Takeda Pharmaceutical

Takeda follows a dual pricing strategy in both private and public markets, and as such, prices in the private market are higher in Europe than in Asian markets

Vault works by inhibiting the production of stomach acid and is approved by the Drugs Controller General of India (DCGI) for the treatment of reflux esophagitis and other acid peptic disorders (APDs)

Biological E will increase manufacturing capacity to up to 50 million doses a year, accelerating Takeda's plans to manufacture 100 million doses annually within the decade

Japanese drug firm Takeda on Tuesday said it has tied up with Hyderabad-based firm Biological E Ltd to manufacture its dengue vaccine. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organisation to achieve zero case-fatality rate due to dengue by 2030, the company said in a statement. The partnership will substantially enhance manufacturing capabilities to ensure a sustainable global supply of the vaccine, it added. Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 million doses annually within the decade, it said. "We are proud to announce a strategic manufacturing partnership with Biological E Ltd which has deep expertise in vaccine manufacturing and longstanding support of public health programmes around the world," Takeda President of the Global Vaccine ...

Japan's Takeda Pharmaceutical is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire, Chief Executive Christophe Weber said

Japan's largest pharmaceuticals company has been selling its over-the-counter (OTC) assets worldwide

Takeda Pharmaceutical Co is selling its subsidiary in Japan focused on consumer healthcare to US investment fund Blackstone Group.

Takeda shares have fallen around 25 per cent since the drugmaker revealed its interest in the acquisition in March

The tie-up is one of the largest ever in the pharmaceuticals sector, crowning a hectic few months of deal-making

Under the deal, Takeda will pay $24 in cash for each Ariad share